Testmate Health, established in 2020 and headquartered in Switzerland, is at the forefront of innovating low-cost, high-quality at-home self-testing solutions. The company is primarily focused on sectors like Biotechnology and Health Care, with a special emphasis on sexual and women's health. Their flagship product is an over-the-counter urine test for common STIs, aimed at curbing rising infection rates by providing accessible, rapid results.
The startup has benefited from an over-subscribed Seed Round, which is propelling the development and validation of their disposable test. Recognition from numerous awards and accelerators—including MassChallenge Switzerland 2019 and Google For Startups Women's Health 2021—highlights their credibility and potential impact. With STI rates soaring and traditional testing barriers prevalent, Testmate Health fills a crucial gap by making testing as convenient and effective as possible. They are poised for significant growth, backed by strategic equity investment expected in December 2025.